Additional clinical-stage programs, including a Phase 2/3 trial in advanced melanoma, underscore momentum across the company’s oncology pipeline Eikon Therapeutics, Inc., a late-stage clinical ...
-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with ...
Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback